经验证阿片类药物误用风险工具的前瞻性筛查显示妇科肿瘤患者误用风险低
本研究对2012年1月至2016年6月在妇科肿瘤或姑息治疗门诊接受阿片类药物处方的妇科癌症患者便利样本进行阿片类药物误用风险工具(ORT)筛查,共118名女性完成筛查。结果显示87%的患者为低风险,7%为中风险,6%为高风险;中高风险患者显著更年轻、更可能患宫颈癌、吸烟及无保险或使用Medicare。作者认为未来筛查可能对宫颈癌患者亚组最有价值。
要点
- 妇科肿瘤患者中87%为阿片类药物误用低风险。
- 中高风险患者显著更年轻(47 vs 58岁,p=0.02)。
- 宫颈癌患者更可能为中高风险(p=0.02),未来筛查可能对该亚组最有价值。
核心结论
- 本队列中大多数妇科肿瘤患者为阿片类药物误用低风险(87%),宫颈癌患者更可能为中高风险,未来筛查可能对该亚组最有价值。
研究设计与样本
- 前瞻性研究,对2012年1月至2016年6月在妇科肿瘤或姑息治疗门诊接受阿片类药物处方的妇科癌症患者便利样本进行ORT筛查,共118名女性,通过病历回顾获取人口学和临床信息,主要结局为ORT风险等级(低 vs 中或高),分类变量采用卡方检验。
主要发现
- 共筛查118名女性,多数为白人(79%),中位年龄57岁;卵巢癌占46%,子宫内膜癌25%,宫颈癌23%,外阴癌4%,阴道癌2%。
- ORT中位评分为1.0分(范围0-10),满分26分;87%为低风险,7%为中风险,6%为高风险。
- 中高风险患者显著更年轻(47 vs 58岁,p=0.02),更可能患宫颈癌(p=0.02)、吸烟(p=0.01)以及无保险或使用Medicare(p=0.03)。
临床怎么用
- 作者认为未来阿片类药物误用筛查可能对宫颈癌患者亚组最有价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize risk for opioid misuse among gynecologic oncology patients. METHODS: The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs. moderate or high). Chi-square tests were performed for categorical variables. RESULTS: A total of 118 women were screened. Most women were Caucasian (79%) with a median age of 57years. Ovarian cancer patients comprised 46% of the cohort with fewer endometrial (25%), cervical (23%), vulvar (4%), and vaginal (2%) cancer patients. The median ORT score was 1.0 (range, 0-10) out of a possible 26. Overall, 87% of patients were categorized as low-risk for opioid misuse, 7% as moderate-risk, and 6% as high-risk. Patients who were at moderate or high-risk of opioid misuse were significantly younger (47 vs. 58years, p=0.02), more likely to have cervical cancer (p=0.02), be smokers (p=0.01) and be uninsured or on Medicare (p=0.03). CONCLUSIONS: Most gynecologic oncology patients in our cohort were low-risk for opioid misuse (87%). Cervical cancer patients were more likely to be moderate to high-risk for misuse. Future screening efforts for opioid misuse may have the highest utility in this subset of patients.
引用
- Garcia C, Lefkowits C, Pelkofski E, et al. Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse. Gynecol Oncol. 2017. PMID: 28807366. doi:10.1016/j.ygyno.2017.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。